The abstract is read at the publisher; the summary is JClub's.
Anti-VEGF-A/PD-(L)1 combinations are approved for advanced renal cell cancer, hepatocellular carcinoma, non-small cell lung cancer, and endometrial cancer, but show limited results in colorectal cancer and glioblastoma.
- Why it matters: The VEGF-A/VEGF-R axis supports tumor angiogenesis and tumor-driven immunosuppression, so blocking it may help shift the tumor microenvironment toward immune-permissive conditions.
- What they did: This review explains the biological rationale for dual VEGF-A and PD-(L)1 blockade, then summarizes clinical evidence across multiple tumor types, including where outcomes have been disappointing.
- The result: The evidence supports use in several cancers with approvals, while highlighting limited efficacy in colorectal cancer and glioblastoma and pointing to emerging strategies to improve responses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.